ReviewFrontiers in oncology2025
Treatment planning for patients with acoustic neuroma.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinician-Guided Deep Learning Segmentation of Skull Base Pneumatization on Computed Tomography Using 3D Slicer and MONAI Label.Life (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Acoustic neuroma (AN) is a benign tumor of the vestibulocochlear nerve, with increasing detection due to improved imaging. Treatment decisions are complex, requiring an individualized approach based on tumor size, location, growth rate, and patient-specific factors such as hearing and vestibular function. Results: Treatment options include observation, microsurgery, and stereotactic radiosurgery. Hearing preservation is prioritized in select cases using middle cranial fossa or retrosigmoid approaches, while translabyrinthine surgery is preferred for larger tumors or disabling dizziness. Stereotactic radiosurgery offers a non-invasive alternative but has variable long-term hearing outcomes and potential tumor regrowth. Vestibular rehabilitation is essential post-treatment, particularly after surgical resection. Discussion: Decision-making depends on patient age, tumor progression, and symptom severity. Younger patients with small tumors may benefit from early intervention to preserve hearing, while older patients with severe imbalance achieve better quality-of-life outcomes with surgery. Stereotactic radiosurgery remains an option for patients unable to undergo surgery, though its long-term efficacy and side effects require careful consideration. A multidisciplinary approach is essential to optimize treatment outcomes. Summary: AN management must be tailored to individual patient profiles. This review integrates current literature and expert clinical experience to guide otolaryngologists, neurologists, and oncologists in treatment planning. Future research should refine treatment algorithms and improve functional outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.